RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review

  • ID: 4284773
  • SWOT Analysis
  • 44 pages
  • GlobalData
1 of 5
RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus gene therapy. It offers products which include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio utilizes its NAV technology platform, a gene delivery technology to develop product candidates. The company offers products for metabolic, muscle, hematologic, ocular and neurodegenerative disorders. Its products are used in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc Key Recent Developments

Aug 08,2017: REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
Jan 06,2017: REGENXBIO Provides Year-End 2016 Corporate Update
Nov 09,2016: REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
Aug 16,2016: Daniel Tasse Appointed to REGENXBIO Board of Directors
Aug 09,2016: REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
  • RegenxBio Inc - Key Facts
  • RegenxBio Inc - Key Employees
  • RegenxBio Inc - Key Employee Biographies
  • RegenxBio Inc - Major Products and Services
  • RegenxBio Inc - History
  • RegenxBio Inc - Company Statement
  • RegenxBio Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • RegenxBio Inc - Business Description
  • RegenxBio Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • RegenxBio Inc - Strengths
  • RegenxBio Inc - Weaknesses
  • RegenxBio Inc - Opportunities
  • RegenxBio Inc - Threats
  • RegenxBio Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • RegenxBio Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 08, 2017: REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
  • Jan 06, 2017: REGENXBIO Provides Year-End 2016 Corporate Update
  • Nov 09, 2016: REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
  • Aug 16, 2016: Daniel Tasse Appointed to REGENXBIO Board of Directors
  • Aug 09, 2016: REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
  • May 05, 2016: REGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights
  • Mar 03, 2016: REGENXBIO Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Operational Progress
  • Mar 01, 2016: REGENXBIO Announces Appointment of Faraz Ali as Chief Business Officer
  • Jan 07, 2016: REGENXBIO Provides Year-End 2015 Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • RegenxBio Inc, Key Facts
  • RegenxBio Inc, Key Employees
  • RegenxBio Inc, Key Employee Biographies
  • RegenxBio Inc, Major Products and Services
  • RegenxBio Inc, History
  • RegenxBio Inc, Joint Venture
  • RegenxBio Inc, Key Competitors
  • RegenxBio Inc, Ratios based on current share price
  • RegenxBio Inc, Annual Ratios
  • RegenxBio Inc, Annual Ratios (Cont...1)
  • RegenxBio Inc, Interim Ratios
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • RegenxBio Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • RegenxBio Inc, Performance Chart (2013 - 2016)
  • RegenxBio Inc, Ratio Charts
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Xencor Inc
  • Proteostasis Therapeutics Inc
  • Alexza Pharmaceuticals Inc
  • Agenus Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll